On Invalid Date, Cytomx Therapeutics (NASDAQ: CTMX) reported Q4 2023 earnings per share (EPS) of $0.01, up 107.69% year over year. Total Cytomx Therapeutics earnings for the quarter were $837.00 thousand. In the same quarter last year, Cytomx Therapeutics's earnings per share (EPS) was -$0.13.
As of Q1 2024, Cytomx Therapeutics's earnings has grown year over year. Cytomx Therapeutics's earnings in the past year totalled -$569.00 thousand.
What is CTMX's earnings date?
Cytomx Therapeutics's earnings date is Invalid Date. Add CTMX to your watchlist to be reminded of CTMX's next earnings announcement.
What was CTMX's revenue last quarter?
On Invalid Date, Cytomx Therapeutics (NASDAQ: CTMX) reported Q4 2023 revenue of $26.61 million up 32.22% year over year. In the same quarter last year, Cytomx Therapeutics's revenue was $20.12 million.
What was CTMX's revenue growth in the past year?
As of Q1 2024, Cytomx Therapeutics's revenue has grown 90.38% year over year. This is 75.23 percentage points lower than the US Biotechnology industry revenue growth rate of 165.61%. Cytomx Therapeutics's revenue in the past year totalled $101.21 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.